MedTrace Logo

The DAWN Antivirals Trial for Ambulatory COVID-19 Patients

NCT04730206 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-10-03

No results posted yet for this study

Summary

This is a prospective, placebo controlled, individually randomized controlled phase III trial in Primary Care, assessing the efficacy of antivirals, i.e. camostat and molnupiravir, in accelerating recovery in Covid-19 patients.

Conditions

  • Covid19
  • SARS-CoV Infection

Interventions

DRUG

Camostat

100 milligram tablets

DRUG

Placebo

oral tablets, identical in size and shape

DRUG

Molnupiravir

200 milligram tablets

Sponsors & Collaborators

  • Universiteit Antwerpen

    collaborator OTHER

  • University Ghent

    collaborator OTHER

  • Université de Liège

    collaborator OTHER

  • Vrije Universiteit Brussel

    collaborator OTHER

  • KU Leuven

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2022-07-13
Completion
2022-07-13

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04730206 on ClinicalTrials.gov